Scarica l'app Stockscreener
73.25
4.11%
2.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$70.36
Aprire:
$72.64
Volume 24 ore:
1.36M
Relative Volume:
1.20
Capitalizzazione di mercato:
$2.05B
Reddito:
$62.60M
Utile/perdita netta:
$-120.74M
Rapporto P/E:
-16.07
EPS:
-4.5586
Flusso di cassa netto:
$-190.35M
1 W Prestazione:
+3.61%
1M Prestazione:
+2.69%
6M Prestazione:
+50.47%
1 anno Prestazione:
+8,883%
Intervallo 1D:
$70.00
$77.00
Intervallo di 1 settimana:
$62.50
$77.00
Portata 52W:
$0.432
$77.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
73.25 | 2.05B | 62.60M | -120.74M | -190.35M | -4.5586 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals - simplywall.st
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - GlobeNewswire Inc.
Nektar Therapeutics stock hits 52-week high at 76.3 USD By Investing.com - Investing.com South Africa
Decoding Nektar Therapeutics (NKTR): A Strategic SWOT Insight - GuruFocus
Nektar Therapeutics jumps on Q4 results - MSN
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
Nektar Therapeutics (NKTR) Q3 Losses Narrow To US$35.5 Million Testing Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026 - Meyka
Oppenheimer raises Nektar Therapeutics price target to $140 By Investing.com - Investing.com Australia
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - bdtonline.com
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com Nigeria
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - TradingView
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics (NKTR) Surges After Beating Q4 Expectations - GuruFocus
Nektar Therapeutics Q4 2025 Earnings Call Summary - Yahoo Finance
William Blair Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $70.36 - 富途牛牛
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript - Insider Monkey
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Q4 2025 earnings preview - MSN
Nektar Therapeutics (NKTR) Reports Q4 and Full Year 2025 Financi - GuruFocus
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Reports 2025 Financial Results and Advances Rezpegaldesleukin to Phase 3 for Atopic Dermatitis - Minichart
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Pro - GuruFocus
Nektar Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion - Investing.com Canada
Nektar (NKTR) Q4 2025 Earnings Call Transcript - AOL.com
Nektar Therapeutics (NKTR) Posts Fourth Quarter Loss, Exceeds Revenue Projections - Bitget
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar (NKTR) Reports Decrease in Q4 Revenue, Prepares for Phase 3 Trials - GuruFocus
Nektar Therapeutics (NASDAQ: NKTR) posts wider 2025 loss but boosts cash via equity raises - Stock Titan
Nektar: Q4 Earnings Snapshot - marketscreener.com
Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c - StreetInsider
Nektar Therapeutics Q4 Swings to Loss, Revenue Declines - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Reports Q4 Revenue $21.8M, vs. FactSet Est of $10.2M - marketscreener.com
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - Bluefield Daily Telegraph
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Class Action Notice: Robbins LLP - GlobeNewswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Carroll County Mirror-Democrat
Nektar Therapeutics Faces Class Action Lawsuit - Intellectia AI
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With - GlobeNewswire
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):